Xarelto Lawsuit Alleges Illinois Woman Suffered Life-Threatening...
The Firm is representing plaintiffs in Xarelto lawsuits who allegedly suffered uncontrollable internal bleeding and other complications related to its use.(PRWeb November 21, 2014)Read the full story at http://www.prweb.com/releases/xolair-lawsuit/xarelto-bleeding/prweb12346384.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 22, 2014 Category: Pharmaceuticals Source Type: news
Roche delivers solid sales growth for the first nine months of 2014
Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives; 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2014 Category: Pharmaceuticals Source Type: news
Roche delivers solid sales growth for the first nine months of 2014
Group sales up 5% at CER, stable in Swiss francs; 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives; 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance (Source: Roche Media News)
Source: Roche Media News - October 16, 2014 Category: Pharmaceuticals Source Type: news
Xolair Side Effect Claims Being Evaluated by Bernstein Liebhard LLP on...
The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots in the...(PRWeb October 01, 2014)Read the full story at http://www.prweb.com/releases/xolair-lawsuit/xolair-side-effects/prweb12216415.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 2, 2014 Category: Pharmaceuticals Source Type: news
FDA Warns on Xolair's (omalizumab) Serious Adverse Events:...
On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. In light of this news,...(PRWeb September 30, 2014)Read the full story at http://www.prweb.com/releases/2014/10/prweb12208816.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 30, 2014 Category: Pharmaceuticals Source Type: news
Small Heart, Stroke Risks From Asthma Drug: FDA
A safety study done by the maker of the asthma drug omalizumab (Xolair) suggests it poses slightly increased but serious risks for heart attacks and mini-strokes known as TIAs (transient ischemic attacks), the FDA says. (Source: WebMD Health)
Source: WebMD Health - September 29, 2014 Category: Consumer Health News Source Type: news
Cardiovascular and Cerebrovascular Warnings Added to Omalizumab's Label (FREE)
By Kristin J. Kelley
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA has updated the label for the asthma drug omalizumab (Xolair) with new warnings about the elevated risk for cardiovascular and cerebrovascular … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 29, 2014 Category: Primary Care Source Type: news
FDA says asthma drug Xolair raises risk of heart, brain problems
WASHINGTON (Reuters) - The asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug Administration said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Warns of Small Cardio, Cerebrovascular Risk With XolairFDA Warns of Small Cardio, Cerebrovascular Risk With Xolair
The agency hedged its warning by saying the findings come from a manufacturer's safety study with 'weaknesses.' News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
FDA approves label changes after review of a five year safety study. (Source: FDA MedWatch)
Source: FDA MedWatch - September 26, 2014 Category: American Health Source Type: news
Omalizumab Effective for Chronic Hives up to 24 WeeksOmalizumab Effective for Chronic Hives up to 24 Weeks
The 300-mg dose of omalizumab was most effective compared with placebo, but symptoms recur after treatment is discontinued. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news
Asthma Drug May Help Those With Chronic Hives
Xolair found safe, effective for reducing symptoms, study finds (Source: WebMD Health)
Source: WebMD Health - July 21, 2014 Category: Consumer Health News Source Type: news
Asthma Drug May Help Those with Chronic Hives
Xolair found safe, effective for reducing symptoms, study finds
Source: HealthDay
Related MedlinePlus Pages: Hives, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 21, 2014 Category: Consumer Health News Source Type: news
Xolair (Omalizumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 10, 2014 Category: Drugs & Pharmacology Source Type: news
FDA approves Xolair® (omalizumab) for people with Chronic Idiopathic Urticaria (CIU), a form of chronic hives
Novartis has announced that the US Food and Drug Administration (FDA) approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (hives) and is not for use in children less than 12 years of age. Xolair is jointly developed by Genentech and Novartis Pharma AG and is co-promoted by Novartis Pharmaceuticals Corporation with Genentech in the United States. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2014 Category: Consumer Health News Tags: Dermatology Source Type: news
